I suppose there’s been interest in what BJ does, because historically this site has followed what he’s been up to. So, no question there is historical interest!
But speaking just for myself, after seeing his justifications for taking a drug/supplement or intervention, I’ve lost interest in what it is that he’s doing or not doing. I have no faith in his approach or methodology.
Again, that’s just me, and I’m sure many others have a different view, and without a doubt, he’s a high profile life extension advocate, so what he does resonates with the public.
3 Likes
adssx
#387
It’s one data point. Like anyone else here. I also stopped Rybelsus last month for similar reasons.
From what I read, he did only 3 weeks? Maybe it would have been more informative if he followed the protocol : 4 weeks at the initial dose, followed by 4 weeks at weight loss dose (whatever that’s defined as) . Elevated heart trate could be transient.
But anyway, not everyone has to be on every drug to extend longevity, and he doesn’t seem to be overweight.
Of course, completely understandable. My unease is from the fact that I don’t know what these small changes in RHR and HRV mean - is this temporary? Apparently BJ didn’t take it for long. I’m thinking about the effect od SGLT2i on egfr kidney. There is the initial dip in the egfr number, but longer term there is a recovery - however, the recovery can take up to a year! And when netted out, SGLT2i generally are beneficial to the kidney (at least if the drug is used before the egfr number gets below 30 or so). What if the Rybelsus agent follows a similar path?
Ultimately of course, the bigger question is how meaningful is the RHR and HRV change if netted out to other benefits. I don’t know. Perhaps, it’s worth the slightly worse numbers in exchange for neurological protection? I don’t know. Longitudinal studies would be nice, but I guess there hasn’t been enough time.
Anyhow, a decision about starting or stopping a drug is individual. I never jumped on this particular class of drugs, because I don’t have enough information about concrete benefits and the reading that I have done (and also the papers cited on this board), have not made a compelling enough case for me. Unlike SGLT2i - I have read up on these and ultimately decided that empagliflozin is worth the gamble. YMMV.
2 Likes
Another once a month glp agonist in the works https://www.nytimes.com/2024/11/26/health/weight-loss-drug-maritide-amgen.html
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Dr. Jay Bradner, the company’s chief scientific officer, noted a surprising effect of the drug: When the trial ended, many participants maintained their weight loss for as long as 150 days. That means that less frequent injections could be possible or even that patients may not need to stay on the drug permanently. The company said it was studying quarterly injections.
And this drug actually inhibits GIP, instead of activating it. Fascinating.
Dr. Bradner said the company decided to block GIP because it had genetic data from Iceland indicating that people who had a variant that stops GIP from working were naturally thinner
1 Like
I’ve heard about it a few months ago on meso-Rx:
1 Like
I took another look at the article and it’s actually quite interesting. The authors found that, at least in pigs, the autonomic nervous system is not involved at all in the change in heart rate. This is in contrast to mice and rats where the autonomic nervous system IS involved. So it could be a rather benign increase via direct action on GLP-1 receptors on the heart.
